Tag: Levobunolol

Over three million Americans have glaucoma, and a significant portion requires medication to manage intraocular pressure. Levobunolol ophthalmic belongs to the class of medications known as beta-blockers and is prescribed to help control this eye pressure.

While the active ingredient is still available in some forms, specific formulations of levobunolol, such as the 0.25% strength and preservative-free unit-doses, have been discontinued. The decision to withdraw these particular products from the market is a complex story involving business factors, market dynamics, and the evolution of glaucoma treatment.